Indonesia to Launch First Plasma Fractionation Facility by Late 2026

Strategic Investment for Healthcare Independence

SKPlasma Core Indonesia, a joint venture between SK Plasma from South Korea and Indonesia Investment Authority (INA), is constructing Southeast Asia's largest plasma fractionation facility in Karawang, West Java. The facility is nearing completion with over 98% construction progress as of December 2025 and is expected to be fully operational by late 2026.

Addressing Current Healthcare Challenges

Currently, Indonesia discards approximately 200,000 liters of plasma annually due to the lack of domestic processing facilities, while importing plasma-derived products at significant costs. The new facility will have the capacity to process 600,000 liters of plasma per year, adopting technology from SK Plasma's facility in Andong, South Korea, which has been operational since 2018.

Economic and Social Impact

The project represents a significant step towards strengthening Indonesia's healthcare system through local production of critical therapies. The facility will manufacture essential plasma-derived medicinal products (PODP) including immunoglobulin for immune deficiencies, albumin for hypoalbuminemia, and Factor VIII for hemophilia A patients. The production is expected to not only meet domestic demand but potentially position Indonesia as a regional exporter of these life-saving therapies.

Technology and Regulatory Compliance

The facility is being built according to Good Manufacturing Practice (GMP) standards set by Indonesia's Food and Drug Administration (BPOM). The project includes comprehensive technology transfer and development of skilled biomedical workforce. SK Plasma has been supplying plasma-derived medicines to 20 countries worldwide, ensuring that the products will meet international quality standards.

Partnership and Implementation

The joint venture between SK Plasma and INA demonstrates a successful public-private partnership model. The collaboration includes working with the Indonesian Red Cross (PMI) for plasma collection. The project is expected to create thousands of new jobs and stimulate local economic development while enhancing national healthcare security.